PRELUDE THERAPEUTICS INC Lessee, Operating Lease, Liability, to be Paid, after Year Five
PRELUDE THERAPEUTICS INC (PRLD) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $19.73 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $19.73M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $19.73M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $23.09M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $23.09M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2026-06-30 | $19.73M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $19.73M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $23.09M 10-K · filed 2026-03-10 |
| 2025-09-30 | $23.09M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $23.09M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $23.09M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $26.38M 10-K · filed 2025-03-10 |
| 2024-09-30 | $26.43M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $26.43M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |